Multi-modality: a new approach for the treatment of major depressive disorder
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Effective treatment with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. Several new multi-modal compounds are in development and early results for the most advanced agents indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and transmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 2×
“Despite these issues, medication compliance is critical, because long-term treatment of MDD decreases the likelihood of relapse by as much as 70% (Rush et al., 2006).”
BackgroundDrevets, W. C., Price, J. L., & Furey, M. L. (2008) · Brain Structure and Function · doi:10.1007/s00429-008-0189-x · Cited by 2,241 · cited 1×
“Second, numerous neural networks and, hence neurotransmitter pathways, have been implicated in the development of MDD (Maletic et al., 2007 ; Drevets et al., 2008).”
BackgroundGlobal burden of depressive disorders in the year 2000
Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. L. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.5.386 · Cited by 1,735 · cited 2×
“…medical and psychiatric co-morbidities (Rush, 2007), has a significant effect on the psychosocial well-being of the patient, reduces productivity in the workplace or at school and has a substantial economic burden on the healthcare system (Ustun et al., 2004 ; Langlieb and Guico-Pabia, 2010).”
BackgroundBang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606 · cited 1×
“Vortioxetine is also a partial agonist at the 5-HT1A receptor as well as a blocker of the SERT, 5-HT3 and 5-HT7 receptors (Bang-Andersen et al., 2011).”
BackgroundNeurocognitive impairment in drug-free patients with major depressive disorder
Porter, R. J., Gallagher, P., Thompson, J. M., & Young, A. H. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.3.214 · Cited by 519
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Mojtabai, R., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.175 · Cited by 479 · cited 1×
“Nonetheless, with the availability of better-tolerated antidepressants, use of antidepressant combinations has become more common (Mojtabai and Olfson, 2010).”
BackgroundNierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709006011 · Cited by 458
Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308 · cited 2×
“…SNRIs with SSRIs in MDD can conflict (some showing equivalency and some showing superiority), metaanalyses of these trials suggest that SNRIs have a modest efficacy advantage and a slightly faster onset of antidepressant action, but with potentially lower tolerability (Papakostas et al., 2007).”
BackgroundResult
Cited by
Pitsillou, E., Bresnehan, S. M., Kagarakis, E. A., Wijoyo, S. J., Liang, J., Hung, A., & Karagiannis, T. C. (2020) · Molecular Biology Reports · doi:10.1007/s11033-019-05129-3 · Cited by 206
Vortioxetine: A Review in Cognitive Dysfunction in Depression
Frampton, J. E. (2016) · Drugs · doi:10.1007/s40265-016-0655-3 · Cited by 90
Wagner, G., Schultes, M.-T., Titscher, V., Teufer, B., Klerings, I., & Gartlehner, G. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.056 · Cited by 61
Metadata
- Authors
- Richelson, E.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07-01
- Volume
- 16
- Issue
- 6
- Pages
- 1433-1442
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2156757671
- Cited by
- 49
- References
- 18
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-modality: a new approach for the treatment of major depressive disorder. https://app.cochat.ai/papers/10.1017/s1461145712001605
- The paper
- Richelson, E. (2013). Multi-modality: a new approach for the treatment of major depressive disorder. International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145712001605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.